Abstract
Colorectal (colon) cancer ranks second in terms of cancer lethality worldwide. It is estimated that approximately 1.93 million new colorectal (colon) cancer cases and approximate one million colorectal cancer deaths occur worldwide in 2020 alone. Cancer metastasis is a major source of cancer lethality. Mechanisms underlying colorectal cancer metastases are long-term obscure. Recently, a new organelle associated with aggressive cancer cells, dubbed cytocapsular tube, was recognized to conduct cancer cell metastases in tissues in vivo. Here, we investigated the roles of cytocapsular tubes in colon cancer metastasis in 9 subtypes of colon cancers with original clinical colon cancer tissues, paracancer tissues of colon cancer, and metastatic colon cancers in multiple other tissues and organs. We found that colon cancer metastasized via cytocapsular tubes and their networks in clinical tissues in vivo. Furthermore, we applied the cytocapsular tube analyses in precise cancer diagnosis in clinical colon cancers and obtained better outcomes in clinical colon cancer management.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The statement is provided
Funding Statement
Supported by a grant (to Dr. Yi) from Cytocapsula Research Institute Fund for Cytocapsular Tube Conducted Cancer Metastasis Research, and a grant (to Dr. Yi) from Cellmig Biolabs Inc Fund for Cytocapsular Tube Cancer Metastasis Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee Member of Cellmig Biolabs Inc decided to waive the ethical oversight of this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos